Search clinical trials for: Oral decitabine/cedazuridine

Total 11188 results

Astex Pharmaceuticals, Inc.

Active, not recruiting

Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

Myelodysplastic Syndromes

Spain, United States, Belgium, Canada, Germany, Italy
Astex Pharmaceuticals, Inc.

Recruiting

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Spain, Poland, Bulgaria, Lithuania, Slovakia, Romania
Astex Pharmaceuticals, Inc.

Recruiting

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Spain, Poland, Bulgaria, Lithuania, Slovakia, Romania
Otsuka Beijing Research Institute

Recruiting

PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

China
Michael Savona
Incyte Corporation; Astex Pharmaceuticals, Inc.; Theradex

Recruiting

Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO) (ABNL-MARRO)

MDS/MPN

United States
Roswell Park Cancer Institute
National Comprehensive Cancer Network

Recruiting

Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8

United States
M.D. Anderson Cancer Center
Genentech, Inc.; Astex Pharmaceuticals, Inc.

Recruiting

Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

United States
Astex Pharmaceuticals, Inc.

Completed

Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndrome | MDS

United States, Canada
M.D. Anderson Cancer Center

Recruiting

Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center

Active, not recruiting

Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent Acute Biphenotypic Leukemia | Refractory Acute Biphenotypic Leukemia

United States
Astex Pharmaceuticals, Inc.

Completed

Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

United States, Canada, Spain, Hungary, Austria, Czechia, France, Germany, Italy, United Kingdom
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University; Taiho Oncology, Inc.

Recruiting

Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

BMS-986253 in Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Otsuka Australia Pharmaceutical Pty Ltd

Recruiting

A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia (PREFER-HMA)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic | Patient Preference

New Zealand, Australia
Astex Pharmaceuticals, Inc.

Enrolling by invitation

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

United States, Spain, Canada, Austria, Slovakia, Bulgaria, Hungary
M.D. Anderson Cancer Center

Recruiting

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Astex Pharmaceuticals, Inc.

Recruiting

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

Chronic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome Positive | BCR-ABL1 Positive Chronic Myelogenous Leukemia | BCR-ABL1 Positive

United States
Astex Pharmaceuticals, Inc.

Active, not recruiting

Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States, Spain, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center

Recruiting

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Recruiting

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Myelodysplastic Syndrome With Excess Blasts | Myeloproliferative Neoplasm

United States, Canada
Case Comprehensive Cancer Center

Not yet recruiting

ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Head and Neck Squamous Cell Carcinoma | Recurrent Squamous Cell Carcinoma of the Head and Neck | Metastatic Squamous Cell Carcinoma

United States
Astex Pharmaceuticals, Inc.

Completed

Effect of Food on Blood Levels of ASTX727

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

United States
Clinical Hub for Interventional Research (CHOIR)
The University of New South Wales; Australian National University

Recruiting

Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS (CELESTIAL-MDS)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

Australia
National Cancer Institute (NCI)

Recruiting

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

Mesothelioma | BRCA1-Associated Protein-1 (BAP1) Mutations | Malignant Mesothelioma (MM) | Early-stage Mesothelioma | Subclinical Mesothelioma | Early-stage BAP1-associated Malignancies

United States
Astex Pharmaceuticals, Inc.

Terminated

A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States
University of Colorado, Denver
National Comprehensive Cancer Network; Taiho Oncology, Inc.

Recruiting

Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma

Malignant Melanoma

United States
Massachusetts General Hospital
Taiho Oncology, Inc.

Recruiting

Inqovi Maintenance Therapy in Myeloid Neoplasms

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | Stem Cell Leukemia

United States
Astex Pharmaceuticals, Inc.

Active, not recruiting

A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Relapsed/Refractory Peripheral T-cell Lymphoma

Spain, United States, Australia, France, United Kingdom, Italy, Poland
H. Lee Moffitt Cancer Center and Research Institute
Blueprint Medicines Corporation

Recruiting

Avapritinib With Decitabine in Patients With SM-AHN

Systemic Mastocytosis With an Associated Hematologic Neoplasm

United States
Washington University School of Medicine
Taiho Oncology, Inc.

Recruiting

Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant

Myelodysplastic Syndromes

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Astex Pharmaceuticals, Inc.

Active, not recruiting

Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

Solid Tumor

United States
Massachusetts General Hospital
Astex Pharmaceuticals, Inc.

Recruiting

ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

Neurological Cancer

United States
Otsuka Pharmaceutical Co., Ltd.

Active, not recruiting

Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes

Lower-risk Myelodysplastic

Japan
Memorial Sloan Kettering Cancer Center
Astex Pharmaceuticals, Inc.

Recruiting

A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)

Malignant Peripheral Nerve Sheath Tumors (MPNST)

United States
Takeda

Withdrawn

A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes (PEVOBINE)

Myelodysplastic Syndromes (MDS)
M.D. Anderson Cancer Center

Not yet recruiting

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Myeloproliferative Neoplasm | Myelodysplastic Neoplasm | Pathway Mutant Myelodysplastic Syndromes

United States
National Cancer Institute (NCI)

Recruiting

Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Astex Pharmaceuticals, Inc.

Terminated

A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

United States
Groupe Francophone des Myelodysplasies
Astex Pharmaceuticals, Inc.

Active, not recruiting

ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients

AML | MDS

France
Race Oncology Ltd
Astex Pharmaceuticals, Inc.

Withdrawn

A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS (BISECT)

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Higher Risk Myelodysplastic Syndrome

Australia
M.D. Anderson Cancer Center

Suspended

A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
Astex Pharmaceuticals, Inc.

Not yet recruiting

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

Allogeneic Stem Cell Transplantation

United States
M.D. Anderson Cancer Center
Astex Pharmaceuticals, Inc.; Syndax Pharmaceuticals

Recruiting

A Phase I-II Study Investigating the All Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

Metastatic Primary Central Chondrosarcoma | Unresectable Primary Central Chondrosarcoma | Locally Advanced Unresectable Primary Central Chondrosarcoma

United States
Sanjay Mohan
National Comprehensive Cancer Network; Taiho Oncology, Inc.

Recruiting

Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant

Recurrent Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Suspended

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Unresectable Triple-Negative Breast Carcinoma

United States
M.D. Anderson Cancer Center
Astex Pharmaceuticals, Inc.

Suspended

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States
Kathy Miller
Pfizer; Astex Pharmaceuticals, Inc.; Van Andel Institute Stand Up to Cancer Team

Completed

Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

Metastatic Breast Cancer | Triple Negative Breast Cancer | Hormone Receptor Positive Tumor

United States

Search clinical trials for: Oral decitabine/cedazuridine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations